查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1763206

全球止血診斷市場

Hemostasis Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球止血診斷市場規模將達到 32 億美元

全球止血診斷市場規模預計在2024年為24億美元，預計到2030年將達到32億美元，在2024-2030年的分析期間內，複合年成長率為4.8%。報告分析的細分市場之一——凝血酶原檢測時間(PT)——預計其複合年成長率為4.6%，到分析期結束時規模將達到13億美元。 D-二聚體細分市場在分析期間的複合年成長率預計為5.7%。

美國市場規模估計為 6.367 億美元，中國市場預計複合年成長率為 8.4%

美國止血診斷市場規模預計在2024年達到6.367億美元。作為世界第二大經濟體，中國市場規模預計到2030年將達到7.363億美元，在2024-2030年的分析期間內，複合年成長率為8.4%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為1.7%和4.8%。在歐洲，預計德國市場的複合年成長率為2.2%。

全球止血診斷市場－主要趨勢與促進因素摘要

止血診斷在患者照護中扮演什麼角色？

止血診斷對於評估血友病、深層靜脈栓塞症和血管性血友病等凝血障礙至關重要。這些診斷可以測量各種凝血因子、血小板功能和凝血時間，為出血性疾病的管理和血栓事件的預防提供寶貴資訊。止血檢測對於術前評估和抗凝血治療的監測也至關重要，準確及時的結果對於病人安全至關重要。出血性疾病正變得越來越普遍，尤其是在人口老化的情況下，這使得止血診斷在常規診療和急診中都變得越來越重要。

為什麼止血診斷技術的進步很重要？

技術進步正在提高止血診斷的準確性和效率。自動凝血分析儀和黏彈性測試等創新技術能夠實現更快、更詳細的評估，這對於管理出血風險至關重要。照護現場設備也越來越普及，使醫護人員能夠在門診進行止血測試並即時獲得結果。這些進步正在提高診斷的速度和準確性，有助於改善患者預後並監測治療效果，尤其是在嚴重情況下。

醫療保健法規如何影響止血檢測？

醫療保健法規在止血診斷中發揮關鍵作用，因為準確可靠的檢測對病人安全至關重要。監管機構對診斷設備和試劑施加了嚴格的品質標準，以確保檢測的可靠性。這些標準是強制性的，鼓勵醫療保健提供者投資符合監管要求的先進診斷設備。這種對合規性的關注推動了對經過認證的高品質止血診斷設備的需求，以確保患者照護的安全有效。

是什麼推動了止血診斷市場的成長？

出血性疾病管理需求的不斷成長、診斷設備的技術進步以及嚴格的醫療法規推動了止血診斷市場的成長。隨著出血性疾病盛行率的上升，對準確及時診斷的需求也日益成長。技術創新提高了診斷的準確性和效率，使這些檢測對於患者安全和有效治療至關重要。監管標準對高品質診斷的要求進一步推動了市場成長，使止血診斷成為患者照護的重要組成部分。

部分

檢驗類型（凝血酶原時間 (PT)、D-二聚體、纖維蛋白原、活化部份凝血活酵素時間）、最終使用者（醫院、診斷中心、其他最終使用者）

受訪公司範例

  • Abbott Laboratories
  • Alere, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Instrumentation Laboratory
  • Nihon Kohden Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用可操作的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP16458

Global Hemostasis Diagnostics Market to Reach US$3.2 Billion by 2030

The global market for Hemostasis Diagnostics estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Prothrombin Test Time (PT), one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the D Dimer segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$636.7 Million While China is Forecast to Grow at 8.4% CAGR

The Hemostasis Diagnostics market in the U.S. is estimated at US$636.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$736.3 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Hemostasis Diagnostics Market - Key Trends & Drivers Summarized

What Role Do Hemostasis Diagnostics Play in Patient Care?

Hemostasis diagnostics are crucial for assessing blood clotting disorders, such as hemophilia, deep vein thrombosis, and von Willebrand disease. These diagnostics measure various clotting factors, platelet function, and coagulation time, providing valuable information for managing bleeding disorders and preventing thrombotic events. Hemostasis testing is also essential for pre-surgical assessments and monitoring anticoagulant therapy, where accurate and timely results are critical for patient safety. As bleeding disorders become more prevalent, particularly with aging populations, hemostasis diagnostics are increasingly important in both routine care and emergency settings.

Why Are Technological Advancements in Hemostasis Diagnostics Important?

Technological advancements are enhancing the accuracy and efficiency of hemostasis diagnostics. Innovations like automated coagulation analyzers and viscoelastic testing are enabling faster, more detailed assessments, which are crucial in managing bleeding risks. Point-of-care devices are also gaining popularity, allowing healthcare providers to perform hemostasis tests in outpatient settings and receive results in real time. These advancements help improve diagnostic speed and accuracy, supporting better patient outcomes and treatment monitoring, particularly in critical care situations.

How Are Healthcare Regulations Impacting Hemostasis Testing?

Healthcare regulations play a significant role in hemostasis diagnostics, as accurate and reliable testing is essential for patient safety. Regulatory agencies enforce strict quality standards for diagnostic instruments and reagents to ensure test reliability. Compliance with these standards is mandatory, prompting healthcare providers to invest in advanced diagnostic equipment that meets regulatory requirements. This focus on regulatory compliance is driving demand for certified, high-quality hemostasis diagnostics, ensuring safe and effective patient care.

What Drives the Growth of the Hemostasis Diagnostics Market?

The growth in the hemostasis diagnostics market is driven by increased demand for bleeding disorder management, technological advancements in diagnostic devices, and strict healthcare regulations. As the prevalence of bleeding disorders rises, there is growing demand for accurate and timely diagnostics. Technological innovations are enhancing diagnostic precision and efficiency, making these tests essential for patient safety and effective treatment. Regulatory standards that mandate high-quality diagnostics are further supporting market growth, positioning hemostasis diagnostics as a critical component of patient care.

SCOPE OF STUDY:

The report analyzes the Hemostasis Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Prothrombin Test Time (PT), D Dimer, Fibrinogen, Activated Partial Thromboplastin Time); End-Use (Hospitals, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • Alere, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Instrumentation Laboratory
  • Nihon Kohden Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Hemostasis Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Hemostasis Testing in Surgical and Critical Care
    • Growth in Point-of-Care Hemostasis Testing Solutions for Rapid Results
    • Advancements in Coagulation Analyzers for Enhanced Precision
    • Expansion of Hemostasis Diagnostics in Hemophilia and Thrombosis
    • Higher Demand for Personalized Hemostasis Testing Solutions
    • Development of Automated Hemostasis Analyzers in Clinical Labs
    • Growth in Demand for Anti-Coagulation Monitoring Solutions
    • Increased Adoption of AI-Driven Hemostasis Data Analytics
    • Expansion of Testing in Pre-Surgical and Critical Care Settings
    • Rising Use of Hemostasis Diagnostics in Blood Disorder Management
    • Growth of Home Testing Options for Hemostasis Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Hemostasis Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Prothrombin Test Time (PT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for D Dimer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Fibrinogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Activated Partial Thromboplastin Time by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • JAPAN
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • CHINA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • EUROPE
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • FRANCE
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • GERMANY
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • INDIA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hemostasis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hemostasis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • AFRICA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030

IV. COMPETITION